Enveda is a five‑year‑old biotechnology company based in Boulder, Colorado. The company announced Phase 1 results in a press release for an oral drug candidate called ENV‑308. Enveda describes the compound as a chemically engineered version of a naturally occurring metabolite associated with exercise biology and positions it as a potential pharmacologic tool to help maintain weight loss while preserving muscle mass.
The announcement reported by STAT was authored by Elizabeth Cooney, Cardiovascular Disease Reporter. The published item includes an image and background context on the discovery that informed the program and notes that additional story content is available behind a STAT+ subscription.
The scientific premise for ENV‑308 rests on a small molecule metabolite known as lactate phenylalanine (lac‑phe). Lac‑phe was identified by Stanford researchers and described in a 2022 Nature paper as an exercise‑induced metabolite that, in animal models, can suppress appetite and lower obesity. Enveda developed ENV‑308 as a chemically modified, orally deliverable compound intended to reproduce the metabolic effects associated with lac‑phe.
According to the company, both lac‑phe and ENV‑308 interact with leptin, a hormone long studied by scientists and drug developers for its role in energy balance and appetite regulation. Enveda frames ENV‑308 as a candidate that would enhance leptin responsiveness — referred to by the company as a “leptin sensitizer in a pill.”
Enveda issued a press release announcing Phase 1 results for ENV‑308. The STAT article summarizes the company’s public positioning and scientific rationale but does not reproduce detailed trial data. The source indicates that the Phase 1 news was presented as early evidence that the compound “has promise,” according to Enveda’s communications.
The STAT piece does not report specific Phase 1 metrics such as the number of participants, dosing regimens, primary or secondary endpoints, quantified safety findings, statistical outcomes, or pharmacokinetic and pharmacodynamic data. Those details were not included in the article sourced here.
Enveda emphasizes two principal therapeutic objectives for ENV‑308. First is maintenance of weight loss by suppressing appetite, echoing the preclinical appetite‑reducing effects reported for lac‑phe. Second is preservation of lean muscle mass — a particular concern raised by the company in the context of current weight‑loss therapies. The article highlights that people who start and stop GLP‑1 receptor agonists may experience loss of lean mass over successive treatment cycles, and Enveda positions ENV‑308 as designed to preserve muscle during weight‑loss maintenance.
Enveda contrasts ENV‑308 with GLP‑1 receptor agonists, which are established agents for weight loss but commonly produce gastrointestinal adverse effects. The company claims the ENV‑308 program aims to provide weight‑loss maintenance benefits without the typical GI side effects associated with GLP‑1 therapies. The STAT summary presents this positioning but does not supply trial evidence comparing tolerability profiles or head‑to‑head data.
The STAT article provides an overview of Enveda’s announcement and the science behind lac‑phe, but it does not include comprehensive Phase 1 trial data in the text available without subscription. Specific information about study population, safety signals, efficacy measures, magnitude of effect, duration of follow‑up, or regulatory plans was not reported in the accessible portion of the article. Readers seeking the full reporting and any additional quotes or details may need access to the STAT+ subscription content or to the company’s original press release and trial registry entries.
In summary, Enveda’s release describes ENV‑308 as an orally administered, lac‑phe–inspired compound that targets leptin signaling with the dual aims of appetite suppression and lean‑mass preservation during weight‑loss maintenance. The announcement reflects early, company‑reported Phase 1 findings; detailed clinical data and independent verification were not presented in the source material reviewed here.